Breaking Headlines

Category archive

Breast Cancer

Luncheon Benefits Breast And Ovarian Cancer Research

in Breast Cancer/medical by
Reading Time: 1 minute

The T.J. Martell Foundation Honors Six Extraordinary Women At The 5th Annual Women Of Influence Awards In New York

Foundation Celebrates Fifth Anniversary Of Annual Event That Recognizes Women Who Have Achieved Outstanding Goals In Business, Family Home And Health

NEW YORK, April 19, 2017 /360WiseNews/ — The T.J. Martell Foundation for Leukemia, Cancer and AIDS research has announced its 2017 Women of Influence Awards which will be held Friday, May 12, 2017 at The Plaza Hotel, Grand Ballroom located at 768 5th Avenue in New York.  The reception will begin at 11:30 a.m. with a luncheon and awards to follow from 12:30 p.m. to 2:00 p.m. The awards celebration will honor six outstanding women who have achieved tremendous goals in business and inspire other women around the globe to live their dreams while balancing work, family, home and health.

Keep Reading

Global Breast Cancer Therapeutics Market Analysis 2016-2022: Company Profiling Covering the Financials, Recent Activities and Future Strategies – Research and Markets

in Breast Cancer/global/Health/Press Release by
Reading Time: 2 minutes

DUBLIN, Mar 01, 2017 /360WiseNews/ —

Research and Markets has announced the addition of the “Global Breast Cancer Therapeutics Market Analysis 2016 – Forecast to 2022” report to their offering.

Research and Markets Logo

The market overview offers in depth analysis at the regional and country level, for instance North America (U.S., Canada and Mexico), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, Australia, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America).

Annual estimations and forecasts are provided from the year 2013 to 2022 for each given segment and sub segments. Market data derived from the authenticated and reliable sources is subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends.

Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, and other activities.

This report provides:

– Market Sizing estimations and forecasts for 6 years across the given market segments
– Identifying market dynamics (Drivers, Restraints, Opportunities, Threats, Challenges and Opportunities, )
– Strategic recommendations in key business segments based on the market estimations
– Regional and country level market analysis
– Competitive landscaping of major market players
– Company profiling covering the financials, recent activities and the future strategies

Key Topics Covered:

1 Introduction
1.1 Scope of the Report
1.2 Report Description
1.3 Research Methodology
1.4 Research Sources
1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Assumptions
1.5 List of Abbreviations

2 Executive Summary

3 Market Analysis
3.1 Market Segmentation
3.2 Market Size Estimation
3.3 Market Drivers
3.4 Market Constraints

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Breast Cancer Therapeutics Market by Clinical Study
5.1 Introduction
5.2 Phase I
5.3 Phase II
5.4 Phase III Drugs

6 Breast Cancer Therapeutics Market by Drug Class
6.1 Introduction
6.2 Mitotic Inhibitors
6.2.1 Ixempra (Ixabepilone)
6.2.2 Halaven (Eribulin)
6.2.3 Taxotere (Docetaxel)
6.3 Anti-metabolites
6.3.1 Gemzar (Gemcitabine)
6.4 Hormone Receptor
6.4.1 Zoladex
6.4.2 Faslodex
6.4.3 Fareston
6.5 Aromatase Inhibitors
6.5.1 Femara (Leterozole)
6.5.2 Arimidex (Anastrozole)
6.5.3 Aromasin (Exemestane)
6.5.4 Ibrance (Palbociclib)
6.5.5 Afinitor (Everolimus)
6.6 HER2 Inhibitors
6.6.1 Kadcyla (Ado-trastuzumab emtansine)
6.6.2 Tykerb (Lapatinib)
6.6.3 Perjeta (Pertuzumab)
6.6.4 Herceptin (Trastuzumab) Keep Reading

Go to Top